Pfizer’s breast cancer drug, Ibrance clinical trial was delayed due to some efficacy issues based on the assessment of independent Data Monitoring Committee (DMC), but after the issues have been solved the clinical trial was continued.
Ibrance also known as palbociclib, the breast cancer drug is undergoing phase 3 study called PALOMA-3 trial and it has met its primary ends and showed improvements in Progression-Free Survival of PFS.
The drug was used in combination with AstraZeneca Plc’s Faslodex or fulvestrant, a widely used drug to block estrogen.
The trial was successful as the patients taking Ibrance with fulvestrant has far better results in disease progression than those taking fulvestrant alone.
The study enrolled patients whose breast cancer had estrogen-receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-)
“The results of this trial are especially important because they help us understand the potential of Ibrance to improve outcomes in patients with this difficult to treat cancer. We’re gratified to be able to stop the trial early,” said DR. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology.
Ibrace drug was able to delay the progression of the drug more effectively when compared to Novartis AG Femara drug.
Pfizer is waiting for the decision of regulatory boards regarding the new breast cancer drug.
Chris Schott, a JPMorgan Chase & Co. said that the Ibrance will make huge sale in the market as the successful clinical trial will give an edge to the drug, which will make it successful in market.
Pfizer is going to make $5B with its new breast cancer drug, says analyst.
Other companies are working on developing a drug that can block cyclin-dependent kinase 4 and 6, a treatment for breast cancer.
Ibrance works by blocking cyclin-dependent kinase 4 and 6.